IGF1 and neoplasm: These data support the hypothesis that in centers devoted to the management of pituitary diseases the choice of second-line therapies may be guided by biochemical markers (as GH and IGF-I levels) and by the tumor mass features (such as invasiveness and residual disease) rather than by the occurrence of systemic complications of acromegaly, such as diabetes mellitus.